Dr. Ron’s Research Review – February 28, 2013

© 2013

This week’s research review focuses on Breast Defend by EcoNugenics.

Breast Defend inhibits proliferation and invasive behavior of the highly metastatic human breast cancer cells in vitro. (Jiang, Wojnowski et al. 2011)

Breast Defend prevents breast-to-lung cancer metastases in an orthotopic animal model of triple-negative human breast cancer. (Jiang, Thyagarajan-Sahu et al. 2012)

Modified citrus pectin with BreastDefend and ProstaCaid showed synergistic and additive effects in the suppression of invasive behavior of human breast and prostate cancer cells respectively in vitro. (Jiang, Eliaz et al. 2012)

Physician formulated by Isaac Eliaz, MD, BreastDefend® is a unique integrative formula designed to promote optimal breast health.

Link

Cellular Support Proprietary Blend

Quercetin (98% bioflavonoids), Scutellaria Barbata, Turmeric (Curcuma longa, BCM-95®), Astragalus membranaceus

950 mg

BreastDefend® Proprietary Herbal Enhanced Mushroom Blend

Coriolus (Trametes versicolor), Reishi (Ganoderma lucidum), Phellinus linteus

500 mg

Diindolylmethane (DIM)

200 mg

Dr. Ron


Articles

Suppression of proliferation and invasive behavior of human metastatic breast cancer cells by dietary supplement BreastDefend

         (Jiang, Wojnowski et al. 2011) Download

AIM: The study was to evaluate the effect of the dietary supplement BreastDefend (BD) on the proliferation and invasive behavior of highly metastatic human breast cancer cells in vitro. METHODS: Cell proliferation and cytotoxicity of BD was evaluated in MDA-MB-231 cells treated with BD (0-40 mug/mL) by MTT assay and trypan blue staining, respectively. Expression of cell cycle regulatory genes were determined by DNA-microarray analysis. Effect of BD on invasiveness was assessed by cellular adhesion, migration, and invasion assays. RESULTS: BD treatment of cells MDA-MB-231 resulted in the cytostatic inhibition of cell proliferation with IC(50) 22.2, 19.1, and 17.5 mug/mL for 24, 48, and 72 hours, respectively. The inhibition of proliferation was mediated by the upregulation expression of CCNG1, CHEK1, CDKN1C, GADD45A, and E2F2, whereas BD downregulated expression of CCNA1 and CDK6 genes. The induction of expression of GADD45A and inhibition of expression of cyclin A1 (gene CCNA1) by BD was also confirmed on the protein level. BD treatment suppressed the invasive behavior of MDA-MB-231 cells by the inhibition of cellular adhesion, migration, and invasion. This inhibition of invasiveness was mediated by the suppression of secretion of urokinase plasminogen activator (uPA), and by the downregulation of expression of CXCR4 in breast cancer cells treated with BD. CONCLUSION: BD inhibits proliferation and invasive behavior of the highly metastatic human breast cancer cells in vitro. BD may have a therapeutic potential for prevention or treatment of highly metastatic breast cancers.


BreastDefend prevents breast-to-lung cancer metastases in an orthotopic animal model of triple-negative human breast cancer

         (Jiang, Thyagarajan-Sahu et al. 2012) Download

We have recently demonstrated that a natural dietary supplement BreastDefend (BD), which contains extracts from medicinal mushrooms (Coriolus versicolor, Ganoderma lucidum, Phellinus linteus), medicinal herbs (Scutellaria barbata, Astragalus membranaceus, Curcuma longa), and purified biologically active nutritional compounds (diindolylmethane and quercetin), inhibits proliferation and metastatic behavior of MDA-MB-231 invasive human breast cancer cells in vitro. In the present study, we evaluated whether BD suppresses growth and breast-to lung cancer metastasis in an orthotopic model of human breast cancer cells implanted in mice. Oral application of BD (100 mg/kg of body weight for 4 weeks) by intragastric gavage did not affect body weight or activity of liver enzymes and did not show any sign of toxicity in liver, spleen, kidney, lung and heart tissues in mice. Moreover, BD significantly decreased the change in tumor volume over time compared to the control group (p=0.002). BD treatment also markedly decreased the incidence of breast-to-lung cancer metastasis from 67% (control) to 20% (BD) (p<0.05) and the number of metastases from 2.8 (0.0, 48.0) in the control group to 0.0 (0.0, 14.2) in the BD treatment group (p<0.05). Finally, anti-metastatic activity of BD in vivo was further confirmed by the downregulation of expression of PLAU (urokinase plasminogen activator, uPA) and CXCR4 (C-X-C chemokine receptor-4) genes in breast tumors. In conclusion, BD may be considered as a biological therapeutic agent against invasive breast cancers.


Synergistic and Additive Effects of Modified Citrus Pectin With Two Polybotanical Compounds, in the Suppression of Invasive Behavior of Human Breast and Prostate Cancer Cells

         (Jiang, Eliaz et al. 2012) Download

Aim. The objective of this study was to evaluate the combined effect of a known galectin-3 inhibitor, PectaSol-C modified citrus pectin (MCP), and 2 novel integrative polybotanical compounds for breast and prostate health, BreastDefend (BD) and ProstaCaid (PC), on invasive behavior in human breast and prostate cancer cells in vitro, respectively. METHODS: The effect of MCP and BD and of MCP and PC on invasiveness was assessed by cell adhesion, cell migration, and cell invasion assays. Secretion of urokinase plasminogen activator (uPA) was determined by Western blot analysis. RESULTS: Although low concentrations of MCP (0.25-1.0 mg/mL) do not suppress cell adhesion of breast or prostate cancer cells, the combination of MCP with BD or PC synergistically inhibits adhesion of these cells. Dose-dependent inhibition of breast and prostate cancer cell migration by MCP (0.25-1.0 mg/mL) is synergistically enhanced by BD (20 microg/mL) and PC (10 microg/mL), respectively. BD or PC did not further inhibit the invasion of breast and prostate cancer cells by MCP; however, the combination of MCP with BD or PC suppressed secretion of uPA from breast and prostate cancer cells, respectively. CONCLUSION: The combination of MCP with BD and of MCP with PC synergistically inhibits the metastatic phenotypes of human breast and prostate cancer cells, respectively. Further studies confirming these observations in animal models of breast and prostate cancer metastasis are warranted.


References

Jiang, J., I. Eliaz, et al. (2012). "Synergistic and Additive Effects of Modified Citrus Pectin With Two Polybotanical Compounds, in the Suppression of Invasive Behavior of Human Breast and Prostate Cancer Cells." Integr Cancer Ther PMID: 22532035

Jiang, J., A. Thyagarajan-Sahu, et al. (2012). "BreastDefend prevents breast-to-lung cancer metastases in an orthotopic animal model of triple-negative human breast cancer." Oncol Rep 28(4): 1139-45 PMID: 22842551

Jiang, J., R. Wojnowski, et al. (2011). "Suppression of proliferation and invasive behavior of human metastatic breast cancer cells by dietary supplement BreastDefend." Integr Cancer Ther 10(2): 192-200 PMID: 20926736